Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) were up 8.4% during trading on Wednesday . The stock traded as high as $17.39 and last traded at $17.40. Approximately 371,403 shares traded hands during trading, a decline of 68% from the average daily volume of 1,151,021 shares. The stock had previously closed at $16.05.
Analyst Upgrades and Downgrades
Several analysts recently commented on VRDN shares. Needham & Company LLC reaffirmed a "buy" rating and set a $36.00 target price on shares of Viridian Therapeutics in a report on Tuesday, May 20th. JMP Securities reduced their target price on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a report on Wednesday, May 7th. Royal Bank Of Canada reduced their target price on shares of Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. The Goldman Sachs Group cut their price objective on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, HC Wainwright reissued a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $37.56.
Check Out Our Latest Research Report on VRDN
Viridian Therapeutics Stock Up 6.2%
The firm's 50-day moving average price is $14.17 and its 200 day moving average price is $15.49. The company has a market capitalization of $1.39 billion, a price-to-earnings ratio of -4.43 and a beta of 0.39. The company has a current ratio of 19.49, a quick ratio of 19.49 and a debt-to-equity ratio of 0.05.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.95) by $0.08. The business had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.16 million. Viridian Therapeutics had a negative net margin of 102,092.39% and a negative return on equity of 70.61%. Viridian Therapeutics's quarterly revenue was up .0% on a year-over-year basis. On average, sell-side analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.
Hedge Funds Weigh In On Viridian Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Foresite Capital Management VI LLC acquired a new position in Viridian Therapeutics in the 4th quarter valued at approximately $38,000. Amalgamated Bank increased its position in Viridian Therapeutics by 49.7% in the 1st quarter. Amalgamated Bank now owns 2,531 shares of the company's stock valued at $34,000 after acquiring an additional 840 shares during the period. AlphaQuest LLC increased its position in Viridian Therapeutics by 119.0% in the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock valued at $54,000 after acquiring an additional 1,519 shares during the period. Summit Investment Advisors Inc. increased its position in Viridian Therapeutics by 24.7% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock valued at $147,000 after acquiring an additional 1,516 shares during the period. Finally, GAMMA Investing LLC increased its position in Viridian Therapeutics by 3,892.9% in the 1st quarter. GAMMA Investing LLC now owns 8,425 shares of the company's stock valued at $114,000 after acquiring an additional 8,214 shares during the period.
Viridian Therapeutics Company Profile
(
Get Free Report)
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.